volv.swiss

Evaluation du site volv.swiss

 Généré le 08 Décembre 2025 14:08

Vieilles statistiques? UPDATE !

Le score est de 54/100

Optimisation du contenu

Titre

Volv Global | Towards better healthcare

Longueur : 39

Parfait, votre titre contient entre 10 et 70 caractères.

Description

Volv Global personalises healthcare by providing insights on patients and diseases powered by data-driven AI and machine learning.

Longueur : 130

Génial, votre balise META description contient entre 70 et 160 caractères.

Mots-clefs

Très mauvais. Nous n'avons pas trouvé de balise META keywords sur votre page. Utilisez ce générateur gratuit de balises META en ligne pour créer des mots-clés.

Propriétés Open Graph

Bien, cette page profite des balises META Open Graph.

Propriété Contenu
locale en_GB
type website
title Volv Global | Towards better healthcare
description Volv Global personalises healthcare by providing insights on patients and diseases powered by data-driven AI and machine learning.
url https://volv.global/
site_name Template
updated_time 2025-11-11T22:19:39+01:00

Niveaux de titre

H1 H2 H3 H4 H5 H6
1 13 57 0 0 0
  • [H1] Where technology meets Human
  • [H2] Shaping the future today for a better tomorrow
  • [H2] Volv Global’s suite of services
  • [H2] Improving lives with better tools and treatments
  • [H2] Insights & Events
  • [H2] Insights & Events
  • [H2] Case studies
  • [H2] How we help you
  • [H2] inTrigue
  • [H2] What we do
  • [H2] Insights
  • [H2] Meet Volv Global
  • [H2] inTrigue
  • [H2] Meet Volv Global
  • [H3] Personalise the patient journey
  • [H3] Target patient populations
  • [H3] Expand medical knowledge
  • [H3] Healthcareefficiencies
  • [H3] Adding value through unprecedented insights
  • [H3] Impact across the product lifecycle​
  • [H3] Clinical Development
  • [H3] Value and Access, HEOR
  • [H3] Medical Affairs
  • [H3] Commercial Excellence
  • [H3] AI Powered Solutions for Rare Disease and Healthcare Innovation
  • [H3] Advanced, proprietary machine learning technology for patient-disease insights
  • [H3] We find more patients
  • [H3] We detect diseases at an earlier stage​
  • [H3] We predict patient outcomes
  • [H3] We stratify patient cohorts
  • [H3] MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification
  • [H3] Bridging gaps across the CLL care pathway – Part 2: Knowing When To Treat
  • [H3] Bridging gaps across the CLL care pathway – Part 1: From Signal to Stratification
  • [H3] PCMG AI Symposium 2025: Cutting Through the Hype – Real Value vs. Overpromised Innovation
  • [H3] Beyond the Hype: Volv Global CEO Christopher Rudolf at Frontiers Health 2025
  • [H3] Cracking the Multiple Myeloma Code: Why Systemic Change is Needed to Match Therapeutic Breakthroughs
  • [H3] MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification
  • [H3] Bridging gaps across the CLL care pathway – Part 2: Knowing When To Treat
  • [H3] Bridging gaps across the CLL care pathway – Part 1: From Signal to Stratification
  • [H3] PCMG AI Symposium 2025: Cutting Through the Hype – Real Value vs. Overpromised Innovation
  • [H3] Beyond the Hype: Volv Global CEO Christopher Rudolf at Frontiers Health 2025
  • [H3] Cracking the Multiple Myeloma Code: Why Systemic Change is Needed to Match Therapeutic Breakthroughs
  • [H3] Where Technology Meets Human: A Call to Unite Clinical Expertise and Real‑World Patient Voices
  • [H3] Unlocking the Future of Type 1 Diabetes Care: Why Earlier Diagnosis Must Match Innovation in Treatment
  • [H3] News Article: AI in healthcare
  • [H3] Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study
  • [H3] World Orphan Drug Congress Europe 2025 | Volv Global in Amsterdam
  • [H3] Optimising Rare Disease Clinical Trials with Real World Data Using NLP & AI: Volv Global at the Rare Trials Summit 2025
  • [H3] Beyond Quick Fixes: How Predictive Modelling Can Redefine Clinical Trial Enrolment
  • [H3] Beyond Initial Treatment: Navigating Recurrence Risk and Clinical Decisions in Cancer Survivors
  • [H3] Unlocking the Full Impact of Breakthrough Therapies in Breast Cancer Through Earlier Detection
  • [H3] Progressive Pulmonary Fibrosis: Solving the Puzzle of Poor Disease Control
  • [H3] Conference Posters: ATS 2025, 17-21 May
  • [H3] Conference Poster: Swiss Biotech Day 2025, 5th-6th May
  • [H3] Unlocking the Power of EMR Data for Earlier Gastric Cancer Diagnosis and Risk Prediction
  • [H3] Press Release: Volv Global Expands Office Footprint to Power Next-Generation AI Innovation in Healthcare
  • [H3] A Rare Disease Day Message from Dr. Al Freedman
  • [H3] Where technology meets Human: Volv Global at the World Orphan Drug Congress USA 2025
  • [H3] News Article: Volv Global Tracks Nearly Undetectable Diseases
  • [H3] White Paper: The Path to Rare Disease Clinical Trial Innovation
  • [H3] Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study
  • [H3] Poster: Alpha-1 Antitrypsin Deficiency: Why millions remain undiagnosed
  • [H3] Finding Patients for Rare Diseases: A Case Study
  • [H3] Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study
  • [H3] Poster: Alpha-1 Antitrypsin Deficiency: Why millions remain undiagnosed
  • [H3] Finding Patients for Rare Diseases: A Case Study
  • [H3] Case Study: Detecting signs of Fabry and Pompe disease in UK clinical data
  • [H3] Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study
  • [H3] Poster: Alpha-1 Antitrypsin Deficiency: Why millions remain undiagnosed
  • [H3] Finding Patients for Rare Diseases: A Case Study
  • [H3] Case Study: Detecting signs of Fabry and Pompe disease in UK clinical data

Images

Nous avons trouvé 14 image(s) sur cette page Web.

4 attribut(s) alt sont vides ou manquants. Ajouter un texte alternatif permet aux moteurs de recherche de mieux comprendre le contenu de vos images.

Ratio texte/HTML

Ratio : 0%

le ratio de cette page texte/HTML est au-dessous de 15 pour cent, ce qui signifie que votre site manque de contenu textuel.

Flash

Parfait, aucun contenu FLASH n'a été détecté sur cette page.

Iframe

Dommage, vous avez des Iframes sur vos pages Web, cela signifie que son contenu ne peut pas être indexé par les moteurs de recherche.

Réécriture d'URLs

Bien. Vos liens sont optimisés!

Tiret bas dans les URLs

Parfait! Aucuns soulignements détectés dans vos URLs.

Liens dans la page

Nous avons trouvé un total de 34 lien(s) dont 0 lien(s) vers des fichiers

Texte d'ancre Type Juice
Skip to content Interne Passing Juice
MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification Externe Passing Juice
Bridging gaps across the CLL care pathway – Part 2: Knowing When To Treat Externe Passing Juice
Bridging gaps across the CLL care pathway – Part 1: From Signal to Stratification Externe Passing Juice
PCMG AI Symposium 2025: Cutting Through the Hype – Real Value vs. Overpromised Innovation Externe Passing Juice
Beyond the Hype: Volv Global CEO Christopher Rudolf at Frontiers Health 2025 Externe Passing Juice
Cracking the Multiple Myeloma Code: Why Systemic Change is Needed to Match Therapeutic Breakthroughs Externe Passing Juice
Where Technology Meets Human: A Call to Unite Clinical Expertise and Real‑World Patient Voices Externe Passing Juice
Unlocking the Future of Type 1 Diabetes Care: Why Earlier Diagnosis Must Match Innovation in Treatment Externe Passing Juice
News Article: AI in healthcare Externe Passing Juice
Webinar: How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: a case study Externe Passing Juice
World Orphan Drug Congress Europe 2025 | Volv Global in Amsterdam Externe Passing Juice
Optimising Rare Disease Clinical Trials with Real World Data Using NLP & AI: Volv Global at the Rare Trials Summit 2025 Externe Passing Juice
Beyond Quick Fixes: How Predictive Modelling Can Redefine Clinical Trial Enrolment Externe Passing Juice
Beyond Initial Treatment: Navigating Recurrence Risk and Clinical Decisions in Cancer Survivors Externe Passing Juice
Unlocking the Full Impact of Breakthrough Therapies in Breast Cancer Through Earlier Detection Externe Passing Juice
Progressive Pulmonary Fibrosis: Solving the Puzzle of Poor Disease Control Externe Passing Juice
Conference Posters: ATS 2025, 17-21 May Externe Passing Juice
Conference Poster: Swiss Biotech Day 2025, 5th-6th May Externe Passing Juice
Unlocking the Power of EMR Data for Earlier Gastric Cancer Diagnosis and Risk Prediction Externe Passing Juice
Press Release: Volv Global Expands Office Footprint to Power Next-Generation AI Innovation in Healthcare Externe Passing Juice
A Rare Disease Day Message from Dr. Al Freedman Externe Passing Juice
Where technology meets Human: Volv Global at the World Orphan Drug Congress USA 2025 Externe Passing Juice
News Article: Volv Global Tracks Nearly Undetectable Diseases Externe Passing Juice
White Paper: The Path to Rare Disease Clinical Trial Innovation Externe Passing Juice
Poster: Alpha-1 Antitrypsin Deficiency: Why millions remain undiagnosed Externe Passing Juice
Finding Patients for Rare Diseases: A Case Study Externe Passing Juice
Case Study: Detecting signs of Fabry and Pompe disease in UK clinical data Externe Passing Juice
Legal Notice Externe Passing Juice
Privacy Policy Externe Passing Juice
Manage options Interne Passing Juice
Read more about these purposes Externe Passing Juice
inTrigue Externe Passing Juice
Meet Volv Global Externe Passing Juice

Mots-clefs

Nuage de mots-clefs

preferences manage intrigue patient insights access title consent global meet

Cohérence des mots-clefs

Mot-clef Contenu Titre Mots-clefs Description Niveaux de titre
patient 6
manage 5
insights 4
access 3
consent 3

Ergonomie

Url

Domaine : volv.swiss

Longueur : 10

Favicon

Trés mauvais. Nous n'avons pas trouvé d'icônes de raccourci. Les icônes sont l'un des moyens faciles d'attirer des visiteurs réguliers plus souvent sur votre site.

Imprimabilité

Aucun style CSS pour optimiser l'impression n'a pu être trouvé.

Langue

Bien. Votre langue est : en.

Dublin Core

Cette page ne profite pas des métadonnées Dublin Core.

Document

Doctype

HTML 5

Encodage

Parfait. Votre charset est UTF-8.

Validité W3C

Erreurs : 0

Avertissements : 0

E-mail confidentialité

Attention! Au moins une adresse e-mail a été trouvée en texte clair. Utilisez une protection anti-spam gratuite pour cacher vos e-mails aux spammeurs.

HTML obsolètes

Génial! Nous n'avons pas trouvé de balises HTML obsolètes dans votre code.

Astuces vitesse

Excellent, votre site n'utilise pas de tableaux imbriqués.
Mauvais, votre site web utilise des styles css inline.
Génial, votre site web contient peu de fichiers CSS.
Mauvais, votre site web contient trop de fichiers javascript (plus de 6).
Parfait : votre site tire parti de gzip.

Mobile

Optimisation mobile

Icône Apple
Méta tags viewport
Contenu FLASH

Optimisation

Sitemap XML

Votre site web dispose d’une sitemap XML, ce qui est optimal.

https://volv.global/sitemap_index.xml

Robots.txt

http://volv.swiss/robots.txt

Votre site dispose d’un fichier robots.txt, ce qui est optimal.

Mesures d'audience

Votre site web dispose d’une outil d'analytics, ce qui est optimal.

   Google Analytics

PageSpeed Insights

Dispositif
Les catégories

Website-SEO-Überprüfung

Website-SEO-Überprüfung est un outil gratuit de référencement qui vous aidera à analyser vos pages web